Movement & fitness

Osteoporosis: fractures, bone density, screening, and treatment trade-offs

8 sources · Latest source check 2026-10-20 UTC

On this page

Osteoporosis makes bones more vulnerable to fracture through changes in density, structure and strength. It can develop without obvious symptoms until a fracture occurs. Low bone density is important information, but fracture risk also needs clinical context; a scan number is not the whole person’s risk assessment.[1]

Similar-sounding measurements have different meanings

Similar-sounding measurements have different meanings
Term	What it measures or describes	Important distinction
DXA / DEXA	A low-dose X-ray assessment of bone mineral density.	A measurement of density, not every contributor to fracture.[2]
T-score	Comparison with a healthy young-adult reference.	Commonly used in postmenopausal women and men aged 50 or older.[2]
Z-score	Comparison with an age-appropriate reference group.	Useful in younger populations; not interchangeable with the T-score.[2]
Fragility-related fracture risk	The likelihood of breaking a vulnerable bone in the clinical context.	History and other risk factors matter as well as a scan.[1]

Bone is living tissue

The body continually removes old bone and forms new bone. Osteoporosis can develop when that balance changes, with loss of bone mass or structural strength. Age, hormones, medical conditions and some medicines affect risk. This is not simply a diagnosis of failing to consume enough calcium.[1]

A person may not notice the condition until a bone breaks. Lack of pain therefore cannot guarantee normal bone health. Conversely, ordinary aches alone do not diagnose osteoporosis. The medical question concerns bone strength, fracture history and relevant testing rather than whether a wellness routine feels beneficial.[1]

Interpreting density and reference scores

MedlinePlus distinguishes T- and Z-score reference groups. A T-score of −2.5 or lower can indicate osteoporosis in the appropriate population. The number needs correct interpretation rather than copying the same label onto every child or younger adult. Testing method, skeletal site and clinical findings also matter.[2]

Risk assessment and treatment planning can consider previous fractures, age and other factors alongside density. BHOF describes a discussion of whether medicines are appropriate and which benefits or risks matter. A borderline score alone does not select one identical treatment for every person.[4]

What the 2025 recommendation actually covers

USPSTF recommends screening women aged 65 or older and postmenopausal women younger than 65 at increased fracture risk. The recommendation concerns adults 40 or older without known osteoporosis or prior fragility fractures. It excludes secondary osteoporosis from medical conditions or bone-loss medicines; those situations need their own assessment.[3]

For men, the task force’s I statement means the evidence is insufficient to judge the screening balance. This is uncertainty about a preventive programme, not proof that screening has no benefit or that a clinician should ignore a fracture or another indication for evaluation. Other jurisdictions can use different guidance.[3]

Nutrition, movement, fall prevention, and medicines have different roles

BHOF describes adequate nutrition, activity, reducing fall hazards and appropriate medicines as parts of care. These address different contributors to fractures. Calcium and vitamin D can be relevant without being a universal cure or a substitute for indicated osteoporosis treatment. A supplement label cannot establish individual fracture protection.[4]

Medicine decisions consider fracture risk, other conditions, previous treatment, adverse effects and preferences. Follow-up and stopping plans can differ between drugs. This article introduces the decision, rather than choosing a medicine or interpreting a reader’s personal DXA result.[4]

A drug-specific warning is not a warning about every treatment

FDA added a boxed warning in 2024 about severe low blood calcium with denosumab in advanced chronic kidney disease, particularly with dialysis or kidney-related mineral/bone disorder. This is a defined drug and population concern, not evidence that every osteoporosis treatment has the same risk.[5]

FDA also warns that stopping or delaying denosumab can increase fracture risk, including spinal fractures. A stopping or replacement plan needs discussion with the treating team. A safety warning should prompt an informed review, rather than becoming an instruction to stop a particular medicine independently.[5]

A heel ultrasound and a central DXA scan are not interchangeable

NIAMS explains that heel ultrasound evaluates bone without measuring bone mineral density; abnormal results may need DXA. Peripheral measurements can improve access but differ in usefulness for fracture prediction or monitoring medication. These tests should retain their specific purpose.[6]

Check whether two DXA measurements can be compared

A repeat scan needs a valid comparison at the relevant skeletal site. The International Society for Clinical Densitometry (ISCD) recommends returning to the same device where appropriate; different machines require cross-calibration before numerical change is reported. The facility’s least significant change is a threshold based on measurement precision. A small difference between printed numbers may therefore be measurement variation rather than established bone loss. Bring the earlier report and ask whether the comparison is valid.[7]

Height or posture changes can raise a spinal-fracture question

A vertebral fracture can compress a spinal bone rather than split it apart. It may cause unexplained back pain, height loss or a more curved posture, but sometimes causes little expected pain. The Royal Osteoporosis Society advises discussing these changes with a doctor so a fracture or another cause can be investigated. Do not assume a new change is ordinary ageing or already explained by an earlier density score.[8]

Evidence & uncertainty

The 2025 US preventive task force supports screening specified groups of women and finds evidence insufficient to determine the balance of screening benefits and harms in men. Insufficient screening evidence is not a statement that men cannot have osteoporosis or never need diagnostic assessment. Treatment and screening are separate questions.[3]

Selected-source overview · Independent review pending

Published questions

Can osteoporosis exist without obvious pain?

Selected-source overview · Independent review pending. Read the evidence context.

Yes. It can be silent until a fracture occurs. Lack of symptoms does not by itself establish normal bone strength.[1]

Evidence behind this answer

Osteoporosis
agency patient explanation · Date not stated
Selected relevant official page passages inspected · Bone remodeling, structure, quiet disease and fracture risk